Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Substrate and target selectivity of 4'-fluoroadenosine against viral and host polymerases.

The Journal of biological chemistry·2026
Same author

Epitope-selective vaccine designs to elicit protective antibodies against the Plasmodium falciparum circumsporozoite protein.

NPJ vaccines·2026
Same author

Vaccination elicits HIV broadly neutralizing antibodies in primates.

Nature·2026
Same author

Translating Innovation to Clinic: End-to-End Bioprocess Development and cGMP Manufacturing of N332-GT5 HIV Vaccine Candidate for First-in-Human Trials HVTN144.

bioRxiv : the preprint server for biology·2026
Same author

The SLC15A4-LAMTOR1 interaction licenses endolysosomal TLR-mediated mTOR signaling and inflammatory cytokine production.

bioRxiv : the preprint server for biology·2026
Same author

Analysis of monoclonal antibodies against the malaria invasion complex protein RIPR reveals the structural basis for synergistic antibody protection.

Immunity·2026

Related Experiment Video

Updated: Mar 18, 2026

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

8.1K

Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles.

Linling He1, Natalia de Val2,3,4, Charles D Morris1

  • 1Department of Immunology and Microbial Science, The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, California 92037, USA.

Nature Communications
|June 29, 2016
PubMed
Summary
This summary is machine-generated.

Developing novel HIV-1 nanoparticle vaccines is crucial for immune recognition. This study presents rationally designed nanoparticles displaying stabilized HIV-1 trimers, showing promise for effective vaccine candidates.

More Related Videos

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

7.4K
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.3K

Related Experiment Videos

Last Updated: Mar 18, 2026

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

8.1K
Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

7.4K
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.3K

Area of Science:

  • Immunology
  • Virology
  • Nanotechnology

Background:

  • The trimeric structure of HIV-1 is critical for immune recognition by broadly neutralizing antibodies (bNAbs).
  • Presenting HIV-1 antigens on nanoparticles offers a promising strategy for vaccine development.

Purpose of the Study:

  • To design, structurally analyze, and antigenically evaluate HIV-1 trimer-presenting nanoparticles.
  • To assess the potential of these nanoparticles as vaccine candidates.

Main Methods:

  • Rational design of nanoparticles displaying stabilized gp140 trimers using ferritin and E2p scaffolds.
  • Confirmation of particle assembly via electron microscopy (EM).
  • Antigenic profiling using bNAbs and non-NAbs, and B cell stimulation assays.

Main Results:

  • Demonstrated presentation of V1V2 and gp120 in native-like trimeric conformations on nanoparticles.
  • Successful assembly of ferritin- and E2p-based nanoparticles displaying gp140 trimers.
  • High-yield production and robust B cell stimulation by gp120 and gp140 nanoparticles.

Conclusions:

  • HIV-1 trimer-presenting nanoparticles can be rationally designed and structurally validated.
  • These nanoparticles serve as a versatile platform for generating multivalent immunogens for HIV-1 vaccine development.